The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Open accessPublished version of a preprint
Abstract
PD-1 immune checkpoint inhibitors have produced encouraging results in patients with hepatocellular carcinoma (HCC). However, what determines resistance to anti–PD-1 therapies is unclear. We created a novel genetically engineered mouse model of HCC that enables interrogation of how different genetic alterations affect immune surveillance and response to immunotherapies. Expression of exogenous antigens in MYC;Trp53−/− HCCs led to T cell–mediated immune surveillance, which was accompanied by decreased tumor formation and increased survival. Some antigen-expressing MYC;Trp53−/− HCCs escaped the immune system by upregulating the β-catenin (CTNNB1) pathway. Accordingly, expression of exogenous antigens in MYC;CTNNB1 HCCs had no effect, demonstrating that β-catenin promoted immune escape, which involved defective recruitment of dendritic cells and consequently impaired T-cell activity. Expression of chemokine CCL5 in antigen-expressing MYC;CTNNB1 HCCs restored immune surveillance. Finally, β-catenin–driven tumors were resistant to anti–PD-1. In summary, β-catenin activation promotes immune escape and resistance to anti–PD-1 and could represent a novel biomarker for HCC patient exclusion. Significance: Determinants of response to anti–PD-1 immunotherapies in HCC are poorly understood. Using a novel mouse model of HCC, we show that β-catenin activation promotes immune evasion and resistance to anti–PD-1 therapy and could potentially represent a novel biomarker for HCC patient exclusion. See related commentary by Berraondo et al., p. 1003. This article is highlighted in the In This Issue feature, p. 983
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a mouse model of HCC, activation of WNT–β-catenin signalling promotes immune escape by impairing recruitment of dendritic cells and interfering with recognition by natural killer cells73.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [73]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 928
Wang, X., Yuan, Z., Li, Z., He, X., Zhang, Y., Wang, X., Su, J., Wu, X., Li, M., Du, F., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1354313 · Cited by 15
Li, J., Bai, Y., Chen, Z., Ying, J., Guo, Y., Fang, W. J., Zhang, F., Xiong, J., Zhang, T., Meng, Z., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03806-2 · Cited by 15
Nayak, A., Streiff, H., Adekoya, O. O., Gonzalez, I., Silva, I., & Shenoy, A. K. (2025) · Cells · doi:10.3390/cells14030178 · Cited by 16
Wang, H., Chen, X., & Calvisi, D. F. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1976142 · Cited by 15
Effects of Ganfule capsule on microbial and metabolic profiles in anti-hepatocellular carcinoma
Xu, F., Li, H., Pan, Y., Zeng, Y., Li, J., & Li, S. (2021) · Journal of Applied Microbiology · doi:10.1111/jam.15307 · Cited by 15
Checkpoint molecules on infiltrating immune cells in colorectal tumor microenvironment
Talaat, I. M., Elemam, N. M., Zaher, S., & Saber-Ayad, M. M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.955599 · Cited by 15
Muñoz, N. M., Dupuis, C. J., Williams, M. L., Dixon, K. A., McWatters, A., Zhang, J., Pavuluri, S., Rao, A. U. K., Duda, D. G., Kaseb, A. O., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-15948-3 · Cited by 15
Multi-omics subtyping of hepatocellular carcinoma patients using a Bayesian network mixture model
Suter, P., Dazert, E., Kuipers, J., Ng, C. K. Y., Boldanova, T., Hall, M. N., Heim, M. H., & Beerenwinkel, N. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009767 · Cited by 16
Multiomics identifies tumor-intrinsic SREBP1 driving immune exclusion in hepatocellular carcinoma
Dadey, R., Li, R., Griner, J., Chen, J., Singh, A., Isett, B. R., Newman, S., Augustin, R. C., Li, A., Manning, J. A., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011537 · Cited by 16
Self-citationZarlashat, Y., Ghaffar, A., Guerra, F., & Picca, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167836 · Cited by 17
The Role of MYC in Tumor Immune Microenvironment Regulation: Insights and Future Directions
Nirala, B. K., & Yustein, J. T. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl37304 · Cited by 19
Aoki, T., Nishida, N., & Kudo, M. (2021) · Journal of Histochemistry & Cytochemistry · doi:10.1369/00221554211056853 · Cited by 15
Fulgenzi, C. A. M., D’Alessio, A., Ogunbiyi, O., Demirtaş, C. Ö., Gennari, A., Cortellini, A., Sharma, R., & Pinato, D. J. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2072726 · Cited by 14
Tanaka, K., Tsuji, K., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2023) · Cancers · doi:10.3390/cancers15174348 · Cited by 14
Hu, Y.-D., Wu, K., Liu, Y., Zhang, Q., Shen, H., Ji, J., Fang, D., & Xi, S.-Y. (2023) · Biology Direct · doi:10.1186/s13062-023-00424-3 · Cited by 14
Wang, F.-Y., Yang, L.-M., Xiong, X.-L., Yang, J., Yang, Y., Tang, J.-Q., Gao, L., Lu, Y., Wang, Y., Zou, T., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00583 · Cited by 15
Belling the “cat”: Wnt/β-catenin signaling and its significance in future cancer therapies
Goyal, A., Murkute, S. L., Bhowmik, S., Prasad, C. P., & Mohapatra, P. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189195 · Cited by 14
Park, H., Park, H., Baek, J., Moon, H., & Ro, S. W. (2022) · Biology · doi:10.3390/biology11040585 · Cited by 14
Wang, Z., Zhang, M., Thompson, H. M., & Ji, H. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00068 · Cited by 14
Advances in experimental animal models of hepatocellular carcinoma
Li, J., Wang, X., Ren, M., He, S., & Zhao, Y. (2023) · Cancer Medicine · doi:10.1002/cam4.6163 · Cited by 14
Vargas‐Accarino, E., Higuera, M., Bermúdez-Ramos, M., Soriano-Varela, A., Torrens, M., Pons, M., Aransay, A. M., Martín, J., Rodríguez‐Frias, F., Merino, X., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062794 · Cited by 13
Tang, Q., Li, L., Ge, J., Wang, D., Qu, H., Wu, J., Wang, Q., Peng, Z., Mo, Y., Wang, Y., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03452-7 · Cited by 13
Breinig, M., Lomakin, A., Heidari, E., Ritter, M. A., Rukhovich, G. D., Böse, L., Butthof, L., Wendler-Link, L., Wiethoff, H., Poth, T., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01437-1 · Cited by 14
Mutational scanning reveals oncogenic CTNNB1 mutations have diverse effects on signaling
Krishna, A., Meynert, A. M., Dolt, K. S., Kelder, M. J. E., Mesropian, A., Ewing, A., Brouwers, C. M., Claassens, J. W. C., Linssen, M. M. L., Sheraz, S., et al. (2026) · Nature Genetics · doi:10.1038/s41588-025-02496-5 · Cited by 14
Self-citationLiang, X., Song, F., Fang, W., Zhang, Y., Feng, Z., Chen, Z., Han, L., & Chen, Z. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s363050 · Cited by 13
HDACs alters negatively to the tumor immune microenvironment in gynecologic cancers
Yan, M., Cao, H., Tao, K., Xiao, B., Chu, Y., Ma, D., Huang, X., Han, Y., & Ji, T. (2023) · Gene · doi:10.1016/j.gene.2023.147704 · Cited by 13
An Integrated Multi-Omics Analysis Identifying Immune Subtypes of Pancreatic Cancer
Su, Y., Wang, F., Lei, Z., Li, J., Ma, M., Yan, Y., Zhang, W., Chen, X., Xu, B., & Hu, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010142 · Cited by 13
Sun, Y.-D., Zhang, H., Li, Y., & Han, J. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189086 · Cited by 13
Werner, W., Kuzminskaya, M., Lurje, I., Tacke, F., & Hammerich, L. (2024) · Seminars in Liver Disease · doi:10.1055/a-2334-8311 · Cited by 14
Xu, L., Liu, Q., Liu, H., Fan, F., Li, P., Yue, S., Mo, J., Liu, Z., Dong, R., Zhang, X., et al. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01328-z · Cited by 13
Gnanamony, M., Demirkhanyan, L. H., Ge, L., Sojitra, P., Bapana, S., Norton, J. A., & Gondi, C. S. (2020) · Oncology Letters · doi:10.3892/ol.2020.12336 · Cited by 13
Wan, Y., Ge, K., Zhou, W., Lu, J., Jia, C., & Zhu, H. (2021) · Biological Chemistry · doi:10.1515/hsz-2020-0328 · Cited by 13
Yang, F., Deng, K., Zheng, H., Liu, Z., & Zheng, Y. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100677 · Cited by 13
Biomarker Development Using Liquid Biopsy in Hepatocellular Carcinoma
Grinspan, L. T., & Villanueva, A. (2022) · Seminars in Liver Disease · doi:10.1055/s-0042-1748924 · Cited by 13
Self-citationKe, C., Chiu, Y., Huang, K., & Lin, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010147 · Cited by 13
Lee, H. K., Nam, M.-W., Go, R., Koo, J., Kim, T. H., Park, J.-E., & Choi, K. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114212 · Cited by 15
Immunotherapy for Hepatocellular Carcinoma in the Setting of Liver Transplantation: A Review
Lominadze, Z., Hill, K., Shaik, M. R., Canakis, J. P., Bourmaf, M., Adams‐Mardi, C., Abutaleb, A., Mishra, L., & Shetty, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032358 · Cited by 13
Advances in Immunotherapy for Hepatocellular Carcinoma
Hagiwara, S., Nishida, N., & Kudo, M. (2023) · Cancers · doi:10.3390/cancers15072070 · Cited by 13
Antony, F., Kang, X., Pundkar, C. Y., Wang, C., Mishra, A., Chen, P., Babu, R. J., & Suryawanshi, A. S. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123043 · Cited by 14
Zou, H., Pan, T., Gao, Y., Chen, R., Li, S., Guo, J., Tian, Z., Xu, G., Xu, J., Ma, Y., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac028 · Cited by 13
Jiang, H., Wei, H., Liang, L., Wang, Y., Kuang, M., Ronot, M., Song, B., & Lee, J. M. (2025) · Liver Cancer · doi:10.1159/000546966 · Cited by 15
Epigenetic mechanisms in HCC immune landscape: Therapeutic implications
Fernández‐Barrena, M. G., Uriarte, I., Sarobe, P., & Avila, M. A. (2025) · Seminars in Immunology · doi:10.1016/j.smim.2025.101980 · Cited by 14
Sidali, S., Campani, C., An, J., Shim, J. H., & Nault, J. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0746 · Cited by 12
Role of the Wnt/β-catenin signaling pathway in the development of HCC
Lin, B., & Li, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1691297 · Cited by 12
Cancer stem cells in hepatocellular carcinoma: therapy resistance and emerging treatments
Yadav, D. K., Yadav, R. K., Singh, A., Huang, Y., Bao, D., Yang, Z., Huang, H., Jiang, Y., Wang, P., Lin, S., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1704868 · Cited by 12
Huo, J., Wu, L., & Zang, Y. (2020) · Medical Science Monitor · doi:10.12659/msm.925494 · Cited by 12
Thomas, A., Slade, K. S., Blaheta, R. A., Markowitsch, S. D., Stenzel, P., Tagscherer, K. E., Roth, W., Schindeldecker, M., Michaelis, M., Rothweiler, F., et al. (2022) · Cancers · doi:10.3390/cancers14071683 · Cited by 12
Tian, B., Yan, L., Ding, Z., Liu, H., Meng, G.-X., Xue, J.-S., Han, C., Dong, Z., Hong, J., Chen, Z., et al. (2022) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2022.2156859 · Cited by 12
Mulé, P., Fernández-Pérez, D., Amato, S., Manganaro, D., Oldani, P., Brandini, S., Diaferia, G. R., Cuomo, A., Recordati, C., Soriani, C., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.06.029 · Cited by 12
NLR stability predicts response to immune checkpoint inhibitors in advanced hepatocellular carcinoma
Du, J., & Huang, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-68048-9 · Cited by 12
Zhao, J., Liu, T., Li, Y., Yang, X., Wang, X., Fu, Y., Zheng, Y., Yao, Z., Wang, J., Gong, H., et al. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.158138 · Cited by 12
Cheng, C., Zha, Q., Sun, L., Cui, T., Guo, X., Xing, C., Chen, Z., Ji, C., Liang, S., Tao, S., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02120-8 · Cited by 14
Lin, S. Y., Chang, T., Steffen, J. D., Chen, S., Jain, S., Song, W., Lin, Y., & Su, Y. (2021) · Diagnostics · doi:10.3390/diagnostics11081475 · Cited by 12
Liu, D., Wu, M., Zhang, T., & Wang, C. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.807502 · Cited by 12
Tang, H., Yang, Q., Tang, Q., Li, X., Ding, W., & Chen, W. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105886 · Cited by 12
Ning, Y., Lin, K., Liu, X., Ding, Y., Jiang, X. W., Zhang, Z., Xuan, Y.-T., Dong, L., Liu, L., Wang, F., et al. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02475-8 · Cited by 12
Lu, G., Du, R., Feng, B., Wang, J., Zhang, F., Pei, J., Wang, Y., & Shang, Y. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s390113 · Cited by 11
Yuan, W. M., Xiao, J., Zhang, J., Mao, B., Wang, P.-Z., & Wang, B.-L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1153353 · Cited by 12
Expression landscape of epigenetic genes in human hepatocellular carcinoma
Castelló-Uribe, B., López-Pascual, A., Elurbide, J., Adán-Villaescusa, E., Valbuena-Goiricelaya, E., Martínez‐Pérez, L. A., Uriarte, I., Latasa, M. U., Sangro, B., Arechederra, M., et al. (2025) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-025-01095-6 · Cited by 11
Eguren‐Santamaría, I., Melero, I., Rodríguez, I., Ortego, I., Armero, M., Gálvez‐Cancino, F., López‐Janeiro, Á., de Andrea, C. E., & Sanmamed, M. F. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011279 · Cited by 13
Real-World Use of Immunotherapy for Hepatocellular Carcinoma
Sara, A., Ruff, S. M., Noonan, A. M., & Pawlik, T. M. (2023) · Pragmatic and Observational Research · doi:10.2147/por.s397972 · Cited by 11
Chen, Y., Yang, C., Sheng, L., Jiang, H., & Song, B. (2023) · Cancers · doi:10.3390/cancers15194677 · Cited by 11
Systemic therapies in hepatocellular carcinoma: A revolution?
Fortuny, M., Sanduzzi‐Zamparelli, M., & Reig, M. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12510 · Cited by 10
Li, Q., Guo, W., Qian, Y., Li, S., Li, L., Zhu, Z., Wang, F., Tong, Y., Xia, Q., & Liu, Y. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008917 · Cited by 11
Dantzer, C., Vaché, J., Brunel, A., Mahouche, I., Raymond, A., Dupuy, J., Petrel, M., Bioulac‐Sage, P., Perrais, D., Dugot‐Senant, N., et al. (2024) · eLife · doi:10.7554/elife.95191.3 · Cited by 11
Hong, K., Cao, J., Jiang, W., Deng, W., Huang, G., Huang, T., Wang, Y., & Wang, Y. (2024) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2024.09.016 · Cited by 11
Inflammation and Immunity in Liver Neoplasms: Implications for Future Therapeutic Strategies
Kim, J., & Seki, E. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0726 · Cited by 11
Lenz, H., Argilés, G., de Jonge, M. J. A., Yaeger, R. D., Doi, T., El-Khoueiry, A. B., Eskens, F. A. L. M., Kuboki, Y., Bertulis, J., Nazabadioko, S., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103729 · Cited by 11
Wei, Y.-G., Yang, C.-K., Wei, Z.-L., Liao, X.-W., He, Y.-F., Zhou, X., Huang, H.-S., Lan, C.-L., Han, C.-Y., & Peng, T. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s344858 · Cited by 11
Hu, Y., Liu, J., Yu, J., Yang, F., Zhang, M., Liu, Y., Ma, S., Zhou, X., Wang, J., & Han, Y. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02514-0 · Cited by 11
Costante, F., Airola, C., Santopaolo, F., Gasbarrini, A., Pompili, M., & Ponziani, F. R. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i9.1622 · Cited by 12
Xu, W., Nie, C., Lv, H., Chen, B., Wang, J., Wang, S., Zhao, J., He, Y., & Chen, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1010554 · Cited by 11
Self-citationHe, Y., Wu, Y., Song, M., Yang, Y., Yu, Y., & Xu, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1149370 · Cited by 11
Tang, X., Luo, B., Huang, S., Jiang, J., Chen, Y., Ren, W., Shi, X., Zhang, W., Shi, L., Zhong, X., et al. (2023) · European journal of medical research · doi:10.1186/s40001-023-01411-0 · Cited by 11
Kan, A., Liu, S., He, M., Wen, D., Deng, H., Huang, L., Lai, Z., Huang, Y., & Shi, M. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100939 · Cited by 11
Zhang, Q., Yu, X., Zheng, Q., He, Y., & Guo, W. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.560229 · Cited by 11
Wang, R., Hu, X., Liu, X., Bai, L., Gu, J., & Li, Q. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249881 · Cited by 11
Wu, S., Zhu, Y., Sun, J., Wang, C.-Y., Wang, Y., Nie, Y.-Y., Song, F., Huang, X., Chen, Z., He, T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65945-z · Cited by 10
Shannon, A. H., Manne, A., Diaz, D. A., & Pawlik, T. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1193762 · Cited by 12
Figg, J., Chen, D., Font, L. F., Flores, C., & Jin, D. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae131 · Cited by 11
Wnt Signaling in Hepatocellular Carcinoma: Biological Mechanisms and Therapeutic Opportunities
Zhu, Y., He, Y., & Gan, R. (2024) · Cells · doi:10.3390/cells13231990 · Cited by 10
Liu, M., Wang, T., & Li, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020625 · Cited by 10
Advancing Adjuvant Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review
Akabane, M., Chatzipanagiotou, O. P., Imaoka, Y., Schenk, A. D., & Pawlik, T. M. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s528709 · Cited by 10
Multidimensional Analysis of CHMP Family Members in Hepatocellular Carcinoma
Guo, Y., Shang, A., Wang, S., & Wang, M. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s350228 · Cited by 10
Self-citationCong, T., Luo, Y., Liu, Y., Yang, C., Yang, H., Li, Y., Li, J., & Li, X. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1000997 · Cited by 10
Wei, Y., Yang, M.-Y., Xu, L., Liu, M.-H., Zhang, F., Xie, T.-S., Cheng, X., Wang, X., Che, F., Li, Q., et al. (2023) · Cancers · doi:10.3390/cancers15030658 · Cited by 12
Novel Molecular Targets for Immune Surveillance of Hepatocellular Carcinoma
Guerra, P., Martini, A., Pontisso, P., & Angeli, P. (2023) · Cancers · doi:10.3390/cancers15143629 · Cited by 11
Inside-Out or Outside-In: Choosing the Right Model of Hepatocellular Cancer
Monga, S. P. (2020) · Gene Expression · doi:10.3727/105221620x15913805462476 · Cited by 10
Self-citationMechanisms and strategies to overcome immunotherapy resistance in hepatobiliary malignancies
Xiong, J., & Wang, Q. (2022) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2022.07.006 · Cited by 10
Molecular Classification of Hepatocellular Carcinoma Using Wnt–Hippo Signaling Pathway-Related Genes
Chang, Y., Chou, Y., Chung, C., Lee, Y.-T., Yen, J.-C., Jeng, L., & Chang, J. (2022) · Cancers · doi:10.3390/cancers14194580 · Cited by 10
Yu, L., Ji, T., Liao, W., Xu, Y., Fang, Y., Zhu, Q., Nie, J., & Yang, D. (2023) · Clinical Epigenetics · doi:10.1186/s13148-023-01460-6 · Cited by 10
Emerging roles for tumor stroma in antigen presentation and anti-cancer immunity
Papadas, A., Huang, Y., Cicala, A., Dou, Y., Fields, M., Gibbons, A., Hong, D., Lagal, D. J., Quintana, V., Rizo, A., et al. (2023) · Biochemical Society Transactions · doi:10.1042/bst20221083 · Cited by 8
UBXN9 inhibits the RNA exosome function to promote T cell control of liver tumorigenesis
Zhang, L., Jiao, K., Liu, Y., Xu, G., Yang, Z., Xiang, L., Chen, Z., Xu, C., Zuo, Y., Wu, Z., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000711 · Cited by 9
SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer
Lachiondo‐Ortega, S., Rejano-Gordillo, C. M., Simón, J., Lopitz‐Otsoa, F., Delgado, T. C., Mazan-Mamczarz, K., Goikoetxea‐Usandizaga, N., Zapata-Pavas, L. E., Río, A. G.-D., Guerra, P., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113924 · Cited by 9
Self-citationArefan, D., D’Ardenne, N. M., Iranpour, N., Catania, R., Yousef, J., Chupetlovska, K., Moghe, A., Sholosh, B., Thangasamy, S., Borhani, A. A., et al. (2024) · Abdominal Radiology · doi:10.1007/s00261-024-04344-2 · Cited by 9
Self-citationOncogenic role of PMEPA1 and its association with immune exhaustion and TGF-β activation in HCC
Piqué‐Gili, M., Andreu-Oller, C., Mesropian, A., Esteban-Fabró, R., Bárcena‐Varela, M., de Galarreta, M. R., Montironi, C., Martinez-Quetglas, I., Cappuyns, S., Peix, J., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101212 · Cited by 9
Self-citationMa, S., Meng, G., Liu, T., You, J., He, R., Zhao, X., & Cui, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117508 · Cited by 9
Hu, L., Wang, Z., Liao, Y., Jiang, X., Lian, H., & Lin, Z. (2024) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000041 · Cited by 9
Immune checkpoint inhibitors: From friend to foe
Rajak, P. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.102033 · Cited by 9
Murphy, K. C., DeMarco, K. D., Zhou, L., Peura, J., Giwa, H. K., Lopez-Diaz, Y., Ho, Y.-J., Li, J., Bai, S., Simin, K. J., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-2532 · Cited by 10
Metadata
- Authors
- Ruiz de Galarreta, M., Bresnahan, E., Molina-Sánchez, P., Lindblad, K. E., Maier, B., Sia, D., Puigvehi, M., Miguela, V., Casanova-Acebes, M., Dhainaut, M., Villacorta-Martin, C., Singhi, A. D., Moghe, A., von Felden, J., Tal Grinspan, L., Wang, S., Kamphorst, A. O., Monga, S. P., Brown, B. D., Villanueva, A., Llovet, J. M., Merad, M., & Lujambio, A.
- Affiliations
- 1Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
- Tisch Cancer Institute (US)
- Icahn School of Medicine at Mount Sinai (US)
- 2Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
- University of Pittsburgh (US)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Lujambio, Amaia
- ORCID
- Ruiz de Galarreta, Marina
- Molina-Sánchez, Pedro
- Lindblad, Katherine E.
- Maier, Barbara
- Sia, Daniela
- Puigvehi, Marc
- Miguela, Verónica
- Casanova-Acebes, María
- Dhainaut, Maxime
- Singhi, Aatur D.
- Moghe, Akshata
- von Felden, Johann
- Wang, Shuang
- Kamphorst, Alice O.
- Monga, Satdarshan P.
- Brown, Brian D.
- Villanueva, Augusto
- Llovet, Josep M.
- Lujambio, Amaia
- Venue
- Cancer Discovery
- Published
- 2019-08-01
- Volume
- 9
- Issue
- 8
- Pages
- 1124-1141
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6677618
- OpenAlex
- W2952311394
- Cited by
- 912
- References
- 67
- Citations by year
- 2026: 114 · 2025: 121 · 2024: 158 · 2023: 169 · 2022: 156 · 2021: 116 · 2020: 67 · 2019: 11
- FWCI
- 36.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Cancer Discovery (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Damon Runyon Cancer Research FoundationDamon Runyon Cancer Research Foundation (Damon Runyon) (DR52-18)
- HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI) (R37CA230636, P30 CA196521)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- β-catenin signaling, hepatocellular carcinoma, immune evasion, anti-PD-1 resistance, PD-1 inhibitors, tumor surveillance, c-Myc, Trp53, dendritic cell recruitment, T cell function, RANTES, chemokines, genetically engineered mouse models, immunotherapy biomarkers
- MeSH terms
- Antineoplastic Agents, Immunological, Animals, Dendritic Cells, Disease Models, Animal, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Oncogenes, Biomarkers, Tumor, Signal Transduction, Gene Expression, Treatment Outcome, CD8-Positive T-Lymphocytes, Drug Resistance, Neoplasm, Tumor Escape, Xenograft Model Antitumor Assays, Cell Line, Tumor, beta Catenin, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
